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ABSTRACT
This study aims to investigate the prognostic power of carcinoembryonic antigen-
related cell adhesion molecule 6 (CEACAM6) in gastric cancer (GC) and its potential 
role in cancer development and progression. Data mining results show that CEACAM6 
is overexpressed in gastric cancer and is correlated with lymph node metastasis. 
Subsequently, immunohistochemical staining was performed to determine CEACAM6 
protein levels in paraffin gastric tumor specimens. Real-time reverse-transcription-
polymerase chain reaction (RT-PCR) was conducted to detect CEACAM6 mRNA levels in 
fresh GC samples. CEACAM6 protein and mRNA levels were significantly up regulated 
in GC compared with paired normal mucosa. The IHC staining intensity of CEACAM6 
was positively correlated with tumor size, Lauren’s classification, vascular invasion, 
lymph node metastasis, distant metastasis, and TNM stage. CEACAM6 expression was 
inversely correlated with the five-year survival rate of GC patients. Cox multivariate 
analysis results demonstrated that the overall survival was independently correlated 
with CEACAM6 expression. A significant association was observed between CEACAM6 
and distant metastases. Network analysis of downstream gene signatures revealed 
several hub genes such as SRC and DNM1L etc. which may mediating tumor promoting 
functions of CEACAM6. Further data mining discovered that Tamoxifen etc. could 
be therapeutic alternatives for gastric patients with CEACAM6 overexpression. 
Collectively, CEACAM6 overexpression is a common characteristic of GC and is 
associated with poor 5 year survival rate in GC. Besides, potential molecular 
mechanisms and treatment options were also provided.
INTRODUCTION
Gastric cancer (GC) is one of the most common 
causes of cancer-related mortality worldwide with 
an estimated 951,600 new cases and 723,100 deaths 
occurred in 2012 [1, 2]. Similar to other malignancies, the 
development of GC is a multi-step process. Early detection 
and appropriate treatment remains promising approach for 
improving the long-term prognosis of patients with GC. 
Despite advances in the diagnosis and treatment of GC in 
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the last decade, prognosis for patients with advanced GC 
remains poor [3, 4].
Various cell adhesion molecules (CAMs) participate 
in the invasion and metastasis process during cancer 
progression [5]. Dysregulation of CAM expression and 
function has been found in malignant transformation. 
Carcinoembryonic antigen-related cell adhesion molecule 
(CEACAM) family are transmembrane glycoproteins 
that belong to the immunoglobulin superfamily. They are 
involved in several biological processes [6], such as cell 
growth, differentiation, cell recognition, immune response, 
and adhesion [7-10]. Different members of the CEACAM 
family may have different functions [11, 12]. There are four 
members of CEACAMs (namely, CEACAM1, CEACAM5, 
CEACAM6 and CEACAM7) have been found in epithelia 
[13]. Theses CEACAMs members can mediate several cell 
signaling pathways and lead to various functions, such as 
tumor suppression/promotion, angiogenesis, lymphocyte 
activation, cell cycle and adhesion [14-16]. CEACAMs are 
often co-expressed in several tumor types. For instance, 
CEACAM 1, 5, and 6 are co-expressed in endometrial, 
lung, ovarian, cervical, breast and colon cancers [17-19].
CEACAM6, also known as CD66c, belongs to 
the carcinoembryonic antigen (CEA) family [20]. It is 
overexpressed in several cancer types (such as ovarian, 
colon, breast and non-small cell lung cancers) and could 
promote cancer progression by inducing epithelial-
mesenchymal transition (EMT) [21-23]. In our previous 
study, we found CEACAM6 was up regulated (ratio ≥ 
2) in gastric tumor tissues by performing the Affymetrix 
GeneChip HG-U133A2.0 array [24]. However, few studies 
have provided information regarding the expression 
patterns of CEACAM6 and their functions in GC.
In this study, we will examine the expression of 
CEACAM6 in GC and normal mucosa, the correlation 
between CEACAM6 expression and clinicopathological 
factors, the prognostic value of CEACAM6 in GC and 
potential molecular functions of CEACAM6 in GC 
progression.
RESULTS
CEACAM6 is overexpressed in gastric cancer 
and is correlated with lymph node metastasis in 
several datasets
To explore the relationship between CEACAM6 and 
gastric cancer, three datasets of gene expression profiles 
(accession: GSE2685, GSE27342 and GSE15459) were 
downloaded from GEO database. Briefly, GSE2685 has 
22 gastric cancer specimens and 8 normal noncancerous 
controls, GSE27342 contains 80 gastric cancer specimens 
and 80 adjacent controls, and GSE15459 has 40 lymph 
node metastasis free (N0) gastric cancer specimens 
and 121 lymph node metastasis positive (Nx) gastric 
cancer specimens. As is shown in Figure 1, CEACAM6 
is overexpressed in gastric cancer samples compared 
to noncancerous gastric mucosa controls in datasets 
GSE2685 and GSE27342 with p=0.0191 and p<0.0001, 
respectively (Left, Middle). Interesting, CEACAM6 is 
also positively correlated with lymph node metastasis of 
gastric cancer (p=0.0134, Figure 1, Right). To sum up, data 
mining results show that CEACAM6 is over expressed in 
gastric cancer and is correlated with cancer metastasis.
IHC validation of the correlation between 
CEACAM6 and GC
Immunohistochemistry results revealed that the 
CEACAM6 protein level was low or negative in the normal 
mucosa (Figure 2A). The proportion of CEACAM6 positive 
specimens was 51.4% (224/436) in the gastric carcinoma 
specimens and yellow-brown CEACAM6 granules were 
observed mainly in the cytoplasm (Figure 2B-2D). The 
proportion of positive CEACAM6 statistically correlated with 
tumor size, Lauren’s classification, vascular invasion, lymph 
node metastasis, distant metastasis, and TNM stage (Table 
1). The ratio of CEACAM6 positivity was 84.4% (120/180) 
in patients with tumor size ≥5 cm, which was higher than the 
ratio in patients with tumor size <5 cm (32.8%, 84/256; p = 
0.000). The frequency of CEACAM6 positive in patients with 
diffused type GC (78.9%, 168/213) was significantly higher 
than that with intestinal type (16.1%, 36/223, p = 0.003). The 
rate of samples positive for CEACAM6 was 62.9% (78/124) 
in gastric carcinoma specimens with poorly differentiated 
tumors, which was higher than that with well to moderately 
differentiated tumors (35.3%, 24/68, p < 0.001). CEACAM6 
was detected in 65.9% (178/270) of GC specimens with 
lymph node metastasis, which was higher compared with 
those without lymph node metastasis (15.7%, 26/166, 
p=0.000). The percentage of samples positive for CEACAM6 
was 90.2% (55/61) in specimens with distant metastasis in 
contrast to those without distant metastasis (39.7%, 149/375, 
p < 0.001). CEACAM6 was also significantly detected in 
5.6% (5/90) in TNM stage I, 19.2% (20/104) in TNM stage 
II, 67.1% (116/173) in TNM stage III, and 91.3% (63/69) in 
TNM stage IV (p < 0.001; Figure 3).
CEACAM6 is correlated with recurrence and 
survival of patients with GC
Kaplan-Meier survival curves indicated that 
patients with high CEACAM6 expression exhibited a 
greater probability of attaining shorter recurrence-free 
survival (p < 0.001, Figure 4A) and overall survival 
(p < 0.001, Figure 4B) than those with low CEACAM6 
expression. This result suggests the possible association of 
CEACAM6 overexpression with poor clinical prognosis. 
The mean recurrence-free survival time in patients 
positive for CEACAM6 was 33.16 ± 1.72 months, which 
is significantly lower than that in patients negative for 
CEACAM6 (53.68 ± 0.82 months, p < 0.001). The mean 
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overall survival time in patients positive for CEACAM6 
was 31.98 ± 1.18 months, which is significantly lower 
than that in patients negative for CEACAM6 (53.17 
± 0.81 months, p < 0.001). In addition to CEACAM6 
expression, tumor stage was also a significant predictor of 
recurrence and overall survival (p < 0.001). These results 
were supported further in a multivariate Cox regression 
analysis, suggesting that the CEACAM6 protein may 
Figure 1: CEACAM6 mRNA expression levels in three different cohort from GEO database. (A) CEACAM6 is over 
expressed in 22 gastric cancer tissues compared to 8 noncancerous gastric tissues in GSE2685 dataset (unpaired t-test, p=0.0191, 228.2±122 
vs 1032±188). (B) CEACAM6 is over expressed in 80 gastric cancer tissues compared to 80 noncancerous gastric tissues in GSE27342 
dataset (p<0.0001, 192.5±39.2 vs 903.7±119.3). (C) mRNA expression levels of CEACAM6 is significantly higher in lymph node positive 
gastric cancer patients (Nx, N=121) than negative patients (N0, N=40) (unpaired t-test, p=0.0134, 6758±1067 vs 10960±899). (D) Real 
time PCR results show that CEACAM6 is significantly higher in cancer tissues compare to paired normal mucosa (paired t-test, p=0.0068).
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be involved in the invasion and progression of human 
GC. Cox multivariate analysis showed that survival was 
independently correlated with CEACAM6 expression (χ2 
= 7.740, p = 0.005; Table 2).
Hub gene analysis of gene signatures regulated 
by CEACAM6
Results in previous sections show that CEACAM6 
over expressed in gastric cancer samples and positively 
correlated with gastric cancer progression. To elucidate 
the potential roles CEACAM6 play in gastric cancer 
development and progression, we obtained downstream 
gene signatures of CEACAM6 from LINCs database. 
Then, gene interaction network was constructed and 
analyzed through GENEMANIA plugin in Cytoscape 
environment. As shown in Figure 5, red bubble indicates 
genes up-regulated by CEACAM6 while green indicates 
down-regulated genes. Grey bubbles means genes 
that connecting up or down regulated genes which are 
regulated by CEACAM6. The size of those bubbles is 
correlated with number of edges connecting each gene. 
Genes connected with three or more other genes are 
defined as hub genes. Full list of hub genes and their 
molecular functions are shown in Table 3 (degree means 
number of edges connecting each gene). These hub genes 
such as SRC (Proto-Oncogene C-Src), DNM1L (Dynamin 
1-Like) and POLR1C (polymerase (RNA) I polypeptide C) 
Figure 2: CEACAM6 staining analysis in normal and gastric cancer tissues. (A) LowCEACAM6 protein expression in normal 
gastric tissue. (B) CEACAM6 protein expressed in tubular adenocarcinoma tissue. (C) CEACAM6 protein expressed in poor differentiated 
GC tissue. (D) CEACAM6 protein expressed in signet-ring cell carcinoma tissue. 1: 40×; 2: 100 ×; 3: 400×, Methods: SP.
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are critical downstream effectors of CEACAM6 in gastric 
cancer progression.
Construction of CEACAM6-drug network
Since CEACAM6 has critical implications in gastric 
cancer development and metastasis, we searched LINCs 
database for available drugs that could down regulated 
CEACAM6 expression. Searching results are displayed 
as a network in Supplementary Figure 1, which shows 
that drugs such as Amsacrine, AG-879 (HER2 inhibitor), 
Wortmannin (PI3K inhibitor) and Tamoxifen could 
repress the expression of CEACAM6. These drugs have 
the potential to be used for managing gastric patients with 
CEACAM6 over expression.
DISCUSSION
Early detection, accurate staging, and constant disease 
monitoring remain the prerequisites of effective treatment 
against GC. Novel GC detection and monitoring methods are 
urgently needed because current biomarkers, such as CA19-9, 
lack enough sensitivity and specificity. The carcinoembryonic 
antigen (CEA) family is overexpressed in various epithelial 
derived cancer types, and their deregulation could promote 
metastasis in animal models [21, 25]. Currently, CEACAM1, 
CEACAM5, and CEACAM6 are considered as valid 
prognostic markers and promising therapeutic targets in 
melanoma, lung, colorectal, and pancreatic cancers [26].
CEACAM6 belongs to of glycosylphosphatidy-
linositol-linked (GPI-linked) Ig superfamily and mainly 
expressed in neutrophils and some epithelial cells [21]. 
Studies demonstrated that CEACAM6 is overexpressed 
in several human malignancies, including colorectal 
adenomas and carcinomas, gastric carcinomas, and 
pancreatic carcinomas etc.[17, 27-29]. In pancreatic 
cancer cells, CEACAM6 overexpression was associated 
with anoikis resistance and tumor metastasis in vitro and 
in vivo [30]. Researchers also tested a single domain 
antibody targeting CEACAM6 that could be an ideal 
candidate for treating pancreatic cancer with CEACAM6 
overexpression [31]. In colon cancer, CEACAM6 
overexpression prevents colonocyte differentiation and 
promotes oncogenesis in nude mice [32]. CEACAM6 is 
Table 1: Correlation between CEACAM6 protein expression and clinicopathological features of GC
Parameters cases CEACAM6 expression χ2 P
Negative (%) Positive (%)
Tumor diameter 48.652 < .001
< 5 256 172 (67.2%) 84 (32.8%)
> =5 180 60 (15.6%) 120 (84.4%)
Lauren classification 172.187 < .001
Diffuse type 223 187 (83.9%) 36 (16.1%)
Intestinal type 213 45 (21.1%) 168 (78.9%)
TNM stage 176.634 < .001
I 90 85 (94.4%) 5 (5.6%)
II 104 84 (80.8%) 20 (19.2%)
III 173 57 (32.9%) 116 (67.1%)
IV 69 6(8.7%) 63 (91.3%)
Vascular invasion 121.548 < .001
No 183 106 (57.9%) 77 (42.1%)
Yes 253 23 (9.1%) 230 (90.9%)
Lymph node metastasis 104.314 < .001
No 166 140 (84.3%) 26 (15.7%)
Yes 270 92 (34.1%) 178 (65.9%)
Distant metastasis 53.594 < .001
No 375 226 (60.3%) 149 (39.7%)
Yes 61 6 (9.8%) 55 (90.2%)
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also overexpressed in breast cancer, and its expression in 
atypical ductal hyperplasia may be a biomarker for the 
invasiveness of breast cancer [33, 34].
Inhibition the expression of CEACAM6 by 
antibodies or RNAi can repress tumor cell growth, 
adhesion, invasion and metastasis, resulting in improved 
survival of mice carrying tumors [29, 33]. Zhang et al. 
demonstrated that CEACAM6 overexpression could 
promote migration and invasion of GC cells in vitro 
and their also showed that CEACAM6 expression was 
correlated with metastases by performing IHC on 101 
pair-matched GC patient samples [35]. A study from 
the same group showed that CEACAM6 could promote 
gastric cancer invasion and metastasis by inducing 
Epithelial-mesenchymal transition [36]. Another research 
group also demonstrated that CEACAM6 was associated 
with the tumorigenesis and lymph node metastasis [37]. 
Recently, a study by Roy and co-authors indicated that 
CEACAM6 could be upregulated by Helicobacter pylori 
CagA and was a biomarker for early gastric cancer [38]. 
However, the sample size of these studies are relatively 
small and validation with a large cohort of GC are needed. 
In this study, we show that the mRNA and protein levels 
of CEACAM6 are significantly up regulated in GC. The 
proportion of CEACAM6 positive patients is 51.4% 
(224/436) in the gastric carcinoma specimens. The protein 
level of CEACAM6 is significantly correlated with tumor 
size, Lauren’s classification, invasion depth, lymph 
node metastasis, distant metastasis, and TNM stage. We 
also find that the median survival time and the five-year 
survival rate in CEACAM6 (+) patients is significantly 
shorter than CEACAM6 (-) patients. These results suggest 
Figure 3: CEACAM6 positive expression distribution in gastric cancer at different TNM stages.
Figure 4: Kaplan-Meier survival curve analysis of patients with gastric cancer positive and negative for CEACAM6 
protein expression (log-rank test). Cumulative recurrence-free survival differences (A) or cumulative overall survival differences 
(B) between patients with high and low levels of CEACAM6 protein expression. The p-value was obtained using the log-rank test of the 
difference.
Oncotarget83679www.impactjournals.com/oncotarget
that CEACAM6 may be used as an predictive biomarker 
of invasion, metastasis, and poor prognosis of GC.
Moreover, the present study provided new insights 
into the multiplicity and diversity of CEACAM6 expression 
and their potential functions in tumor development and 
Figure 5: Downstream molecular interaction network regulated by CEACAM6. Red bubble indicates genes up-regulated by 
CEACAM6 while green indicates down-regulated genes. Grey bubbles means genes that connecting up or down regulated genes which are 
regulated by CEACAM6. Genes connected with three or more other genes are defined as hub genes which probably play critical functions 
in the downstream signal network of CEACAM6 (Graph was drawn using Cytoscape software).
Table 2: Cox multivariate analysis of factors associated with GC survival
Factor B-value SE-value Wald p-value
Tumor diameter 0.13 0.137 0.905 0.341
Lauren classification 0.336 0.211 2.751 0.115
Histology classification -0.012 0.089 0.017 0.896
Differentiation 0.012 0.135 0.008 0.93
Lymph node metastasis 0.294 0.284 1.071 0.301
Distant metastasis 0.334 0.21 2.526 0.112
TNM stage 0.501 0.184 7.41 0.006**
CEACAM6 protein expression 0.49 0.176 7.74 0.005**
**p < 0.05
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progression. The median survival (recurrence and overall) 
time and five-year survival rate in CEACAM6 positive 
patients were significantly lower than CEACAM6 negative 
patients. Multivariate cox analysis results further showed 
that overall survival was independently correlated with 
CEACAM6 expression.
Network analysis of downstream gene signatures 
of CEACAM6 discovered several hub genes which may 
play critical roles in mediating tumor proliferation and 
metastasis. Of those hub genes, DNM1L is a member of 
the dynamin superfamily of GTPases, and is involved in 
developmentally regulated apoptosis and programmed 
necrosis [39]. Dysfunction of this gene is implicated in 
several neurological disorders, including Alzheimer’s 
disease [40]. Recent studies show that DNM1L could 
repress apoptosis of cancer cells and promote migration 
and invasion in breast cancer [41-43]. However, the 
function of DNM1L in gastric cancer has never been 
explored. This gene can be an important downstream 
effector of CEACAM6 and mediating gastric cancer 
progression. Furthermore, we found several available 
drugs that could inhibit the expression of CEACAM6, 
which in turn may lead to the repression of gastric cancer 
progression. For instance, Tamoxifen is the most widely 
used drug in breast cancer management with barely no 
side effects [44, 45]. The application of Tamoxifen in 
combination with traditional chemotherapeutics in the 
treatment for CEACAM6 over expression gastric cancer 
patients may generate positive benefits.
In summary, CEACAM6 overexpression is a 
common characteristic in GC and is positively associated 
with metastasis and poor prognosis of GC. Currently 
available drugs such as Tamoxifen and AG-879 could 
be used for managing patients with CEACAM6 over 
expression. Nevertheless, further wet lab experiments 
and appropriately designed clinical trials are still needed 




All of the study protocols in this study were 
approved by the Institutional Ethics Committee of the 
Zhejiang Provincial People’s Hospital, Hangzhou, China. 
Written informed consent was obtained from the next of 
kin, caretakers, or guardians on behalf of minors/child 
participants. Permission for using the information in the 
medical records of the patients for research purposes was 
obtained from the Zhejiang Provincial People’s Hospital. 
The Institutional Ethics Committee of the Zhejiang 
Provincial People’s Hospital also ensured that relevant 
ethical issues in this study were considered.
Datasets
Gene expression profiles of gastric cancer samples 
and normal controls were obtained from GEO (Gene 
Expression Omnibus: http://www.ncbi.nlm.nih.gov/geo/) 
database [46]. Accession number: GSE2685 (22 gastric 
cancer specimens vs 8 normal noncancerous controls), 
Table 3: Hub genes of downstream signaling network regulated by CEACAM6
Gene symbol Function Degree Regulation
SRC regulation of T cell activation|apoptotic signaling pathway 9 Up
DNM1L regulation of apoptotic signaling pathway 8 Up
POLR1C transcription initiation from RNA polymerase I promoter 7 Down
PEX11A peroxisome organization 6 Down
EGF ERK1 and ERK2 cascade|growth factor receptor binding 5 Down
MNAT1 G1/S transition of mitotic cell cycle 5 Down
PTPN6 regulation of ERK1 and ERK2 cascade 5 Down
PTK2B stress-activated MAPK cascade 5 Down
CDC42 regulation of T cell activation 5 Up
MAPK9 positive regulation of immune response|MAPK cascade 4 Down
MAT2A methionine adenosyltransferase activity 4 Down
PPP2R5E Wnt Signaling Pathway 4 Up
TFDP1 G1/S transition of mitotic cell cycle 3 Up
FOS positive regulation of immune response|MAPK cascade 3 Down
CEBPZ Direct p53 effectors 3 Up
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GSE27342 (80 gastric cancer specimens vs 80 normal 
noncancerous controls) [47] and GSE15459 (40 lymph node 
metastasis free gastric cancer specimens vs 121 lymph node 
metastasis positive gastric cancer specimens) [48]. Gene 
signatures regulated by CEACAM6 and Drugs targeting 
CEACAM6 were obtained from LINCs database [49].
Tumor samples
The paraffin specimens of tumors were obtained 
from 436 patients with GC (17 to 91 years old, no 
radiotherapy or chemotherapy treatment before operation) 
who underwent curative gastrectomy between 1998 and 
2004 at the Department of General Surgery (Zhejiang 
Provincial People’s Hospital, Hangzhou, China). All of the 
cases were classified according to the WHO Pathological 
Classification of Tumors. Patients were follow up for over 
five years after operation. Detailed information about 
these samples are described previously [50].
In addition, 48 fresh frozen cancer tissues and 
surrounding normal gastric mucosa were obtained from 
patients with GC at Zhejiang Provincial People’s Hospital 
from January 2007 to December 2008 and stored at -80°C 
until use.
Immunohistochemical staining and evaluation
Immunohistochemical staining of CEACAM6 
was performed with rat anti-human CEACAM6 (1:150, 
Abcam, GBR) using protocols described in detail 
previously [51]. Immunohistochemically stained sections 
were reviewed and evaluated by two independent 
pathologists. All of the slides were observed under a Nikon 
light microscope (Nikon Corporation, Tokyo, Japan), and 
representative photographs were captured.
Real-time PCR
Real-time PCR was conducted according to the 
user’s manual of the PCR kit. In brief, total RNA was 
extracted from the fresh cancer tissues and the surrounding 
normal gastric mucosa by using Trizol reagent (Invitrogen, 
USA). To generate cDNA, 1μg total RNA was reverse-
transcribed using PrimeScript First Strand cDNA Synthesis 
kit (Takara, DRR047A, Japan) in a total reaction volume 
of 20 μl according to the manufacturer’s instructions. Real-
time PCR was performed using the MX3000P Real-time 
RCR Detection System (Stratagene, USA) by using gene-
specific primers with SYBR Premix ExTaq kit (Takara, 
Japan). The forward and reverse primer of CEACAM6 
were 5’-GGGTATCGCTGAGACTAAGTTGTA-3’ 
and 5’-CCTTAGGCAAGATACAAACCAAC-3’, 
respectively. Human glyceraldehyde-3-phosphate dehydro 
genase (GAPDH) was used as an internal control for 
real-time PCR. The primer sequence of GAPDH was 
5’-cgattggatggtttagtgagg-3’ (forward) and 5’-agttcgaccgt 
cttctcagc-3’ (reverse; Invitrogen).
After 30 s of initial denaturation at 95 °C, 40 cycles 
of amplification were performed at 95 °C for 5 s, 55 °C 
20 s, and 70 °C for 20 s. At the end of the PCR cycles, 
melting curve analyses were performed. The intensity of 
the dye fluorescence was determined, and the expression 
levels of these mRNAs in relation to GAPDH were 
calculated using 2-ΔCt method.
Statistical and bioinformatics analyses
Data were statistically analyzed using SPSS 
software (Version 21.0). Results were presented as mean 
± standard deviation (SD); Paired sample t-test or one-
way ANOVA was employed as appropriate. Categorical 
variables were presented as percentages and analyzed by 
Fisher’s exact test. Survival curves were plotted using 
Kaplan-Meier method and compared hazards method.
Gene expression profiles were processed through 
R software [52]. Scatter plots and related statistical 
analyses were made through Graphpad prism (version 
5.0, GraphPad Software, Inc). GENEMANIA plugin 
[53] in Cytoscape environment (version 3.1.1) [54] was 
employed to build the interaction network of CEACAM6 
regulated gene signatures. Hub gene was defined as genes 
that interacts with 3 or more other genes. CEACAM6-
drug network was also constructed using Cytoscape. All 
p-values resulted from the use of two-sided statistical tests, 
and differences were considered significant at p < 0.05.
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